Prostate cancer screening: what can we learn from randomised trials?
- PMID: 29594015
- PMCID: PMC5861281
- DOI: 10.21037/tau.2017.12.13
Prostate cancer screening: what can we learn from randomised trials?
Abstract
In this article, the principle of randomised trials are first described and then prostate cancer screening trials published to date are evaluated based on these principles. A summary of the randomised prostate cancer screening is provided. The conclusion that can be made from the results of the screening trials, as well as limitations of the evidence and open questions are outlined in the end.
Keywords: Prostate cancer screening; effectiveness; screening trials; validity.
Conflict of interest statement
Conflicts of Interest: The author has no conflicts of interest to declare.
Similar articles
-
Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.PLoS One. 2019 Nov 5;14(11):e0224479. doi: 10.1371/journal.pone.0224479. eCollection 2019. PLoS One. 2019. PMID: 31689326 Free PMC article. Clinical Trial.
-
Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group.Eur J Cancer. 1999 Feb;35(2):262-71. doi: 10.1016/s0959-8049(98)00379-7. Eur J Cancer. 1999. PMID: 10448269 Review.
-
Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.Eur Urol Focus. 2019 Mar;5(2):186-191. doi: 10.1016/j.euf.2017.07.007. Epub 2017 Aug 10. Eur Urol Focus. 2019. PMID: 28803925 Free PMC article. Clinical Trial.
-
Health-related quality of life and cost-effectiveness studies in the European randomised study of screening for prostate cancer and the US Prostate, Lung, Colon and Ovary trial.Eur J Cancer. 2001 Nov;37(17):2154-60. doi: 10.1016/s0959-8049(01)00288-x. Eur J Cancer. 2001. PMID: 11677101 Review.
-
[The unreasonableness of prostate-cancer screening and the ethical problems pertaining to its investigation].Ned Tijdschr Geneeskd. 2005 Apr 30;149(18):966-71. Ned Tijdschr Geneeskd. 2005. PMID: 15903036 Dutch.
Cited by
-
Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.PLoS One. 2019 Nov 5;14(11):e0224479. doi: 10.1371/journal.pone.0224479. eCollection 2019. PLoS One. 2019. PMID: 31689326 Free PMC article. Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources